PRKAA2 and cystic kidney disease: Studies have shown that some but not all compounds associated with the activation of AMPK attenuate cystic kidney disease in Pkd1 mutant animal models (Takiar et al., 2011; Chiaravalli et al., 2016; Kipp et al., 2016; Riwanto et al., 2016; Warner et al., 2016; Leonhard et al., 2019; Lian et al., 2019; Torres et al., 2019; Pastor-Soler et al., 2022).